Paper42436136
Specimen quality shapes the actionable genomic landscape in comprehensive cancer genomic profiling.
Nakahara H and 6 others. NPJ Genom Med, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Specimen quality shapes the actionable genomic landscape in comprehensive cancer genomic profiling. Papers, record 42436136. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42436136
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Specimen quality shapes the actionable genomic landscape in comprehensive cancer genomic profiling.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| JP26K18769 | Japan Society for the Promotion of Science | PubMed |
Source PubMed
References43
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40783289 | Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial. | Lancet | 2025 | https://conductscience.org/library/papers/40783289 | PubMed |
| 2 | 40335734 | The usefulness of comprehensive genome profiling test in screening of Lynch syndrome independent of the conventional clinical screening or microsatellite instability tests. | J Hum Genet | 2025 | https://conductscience.org/library/papers/40335734 | PubMed |
| 3 | 33431880 | Construction and integration of three de novo Japanese human genome assemblies toward a population-specific reference. | Nat Commun | 2021 | https://conductscience.org/library/papers/33431880 | PubMed |
| 4 | 36040493 | Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/36040493 | PubMed |
| 5 | 40938919 | Analytical validation (accuracy, reproducibility, limit of detection) and gene expression analysis of FoundationOneRNA assay for fusion detection in 189 clinical tumor specimens. | PLoS One | 2025 | https://conductscience.org/library/papers/40938919 | PubMed |
| 6 | 34339623 | Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. | Lancet Oncol | 2021 | https://conductscience.org/library/papers/34339623 | PubMed |
| 7 | 37795443 | The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality. | Front Oncol | 2023 | https://conductscience.org/library/papers/37795443 | PubMed |
| 8 | 28132688 | InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. | Am J Hum Genet | 2017 | https://conductscience.org/library/papers/28132688 | PubMed |
| 9 | 39939621 | Real-world data analysis for factors influencing the quality check status in FoundationOne CDx cancer genomic profiling tests. | Sci Rep | 2025 | https://conductscience.org/library/papers/39939621 | PubMed |
| 10 | 33762738 | Clinical cancer genomic profiling. | Nat Rev Genet | 2021 | https://conductscience.org/library/papers/33762738 | PubMed |
| 11 | 36328033 | Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14). | Lancet Gastroenterol Hepatol | 2023 | https://conductscience.org/library/papers/36328033 | PubMed |
| 12 | 37256976 | Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. | N Engl J Med | 2023 | https://conductscience.org/library/papers/37256976 | PubMed |
| 13 | 40140952 | Real-World Data Analysis of Genomic Alterations Detected by a Dual DNA-RNA Comprehensive Genomic Profiling Test. | Cancer Sci | 2025 | https://conductscience.org/library/papers/40140952 | PubMed |
| 14 | 40634197 | Genomic Landscape of Resected Invasive Mucinous Adenocarcinoma of the Lung. | Clin Lung Cancer | 2025 | https://conductscience.org/library/papers/40634197 | PubMed |
| 15 | 37276871 | Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. | Lancet Oncol | 2023 | https://conductscience.org/library/papers/37276871 | PubMed |
| 16 | 36746967 | Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. | Nat Commun | 2023 | https://conductscience.org/library/papers/36746967 | PubMed |
| 17 | 32788553 | Cancer genomic medicine in Japan. | Proc Jpn Acad Ser B Phys Biol Sci | 2020 | https://conductscience.org/library/papers/32788553 | PubMed |
| 18 | 40848312 | The emerging role of PARP inhibitors in prostate cancer: A narrative review. | Cancer Treat Rev | 2025 | https://conductscience.org/library/papers/40848312 | PubMed |
| 19 | 39366135 | Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development. | Cancer Treat Rev | 2024 | https://conductscience.org/library/papers/39366135 | PubMed |
| 20 | 32213540 | Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. | Cancer Discov | 2020 | https://conductscience.org/library/papers/32213540 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| KRAS | 3845 | PubTator's text mining | https://conductscience.org/library/genes/3845 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42436136
GET https://conductscience.org/api/papers/v1/42436136/references?page=2